SuzanneLouiseTopalianMD
General Surgery • Baltimore, MDSurgical Oncology (Other than Breast)
Professor of Surgery, Professor of Oncology, Johns Hopkins University School of Medicine; Melanoma Program Director
Are you Dr. Topalian?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 62 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1800 Orleans Street
Baltimore, MD 21287
Summary
- Dr. Suzanne Topalian, MD is a general surgeon in Baltimore, Maryland. She is currently licensed to practice medicine in Maryland and Pennsylvania. She is affiliated with Johns Hopkins Hospital and Johns Hopkins Howard County Medical Center.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1987 - 1989- Clinical Center at the National Institutes of HealthResidency, Surgery, 1985 - 1986
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Surgery, 1983 - 1985
Pennsylvania Hospital of the University of Pennsylvania Health SystemResidency, Surgery, 1982 - 1983- Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Surgery, 1979 - 1982
Tufts University School of MedicineClass of 1979
Certifications & Licensure
MD State Medical License 2006 - 2025
PA State Medical License 1981 - 2014
Clinical Trials
- Vaccine Therapy in Treating Patients With Metastatic Melanoma Start of enrollment: 1999 Jul 01
- Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma Start of enrollment: 2003 Jan 01
Publications & Presentations
PubMed
- A minimal gene set characterizes TIL specific for diverse tumor antigens across different cancer types.Zhen Zeng, Tianbei Zhang, Jiajia Zhang, Shuai Li, Sydney Connor
Nature Communications. 2025-02-03 - Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II...Shailender Bhatia, Suzanne L Topalian, William Sharfman, Tim Meyer, Neil Steven
Journal of Clinical Oncology. 2025-01-31 - Neoadjuvant anti-PD-1-based immunotherapy: evolving a new standard of care.Suzanne L Topalian, Drew M Pardoll
Journal for Immunotherapy of Cancer. 2025-01-23
Press Mentions
Tip Sheet: Johns Hopkins Kimmel Cancer Center Researchers to Present at Asco Annual MeetingMay 26th, 2023- Hopkins Immunotherapy Researchers Named Fellows of the SITC Academy of Immuno-OncologySeptember 19th, 2022
- Dragonfly Therapeutics Expands Leadership Team with Chief Operating Officer and Also Strengthens Scientific Advisory BoardNovember 24th, 2020
- Join now to see all
Grant Support
- Recognition Of Self And Mutated Self By Autoimmune And Tumor-Specific TcrsNational Institute Of Allergy And Infectious Diseases2010–2011
- B7-H1/Pd-1 Modulation In Cancer TherapyNational Cancer Institute2010–2011
- Recognition Of Self And Mutated Self By Autoimmune And Tumor-Specific TcrsNational Institute Of Allergy And Infectious Diseases2008–2009
Other Languages
- French
